Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Terns Pharmaceuticals, Inc. - Common Stock (NQ:TERN)

37.79 +0.04 (+0.11%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Terns Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Should You Invest in This Under-the-Radar Weight Loss Stock? ↗
Getting in on the ground floor sounds like a great idea, but not if the building ends up crumbling. 
Via The Motley Fool
News headline image
1 New Weight Loss Drug Stock to Buy Now With $1,000 and Hold for 5 Years or More ↗
This biotech's data suggests that it could have an advantage in its target market. 
Via The Motley Fool
News headline image
Calavo Growers Posts Better-Than-Expected Earnings, Joins Tesla, Oracle, Mission Produce And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Oracle To Rally Around 29%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
Terns Pharmaceuticals, Boeing, Tesla And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Top 2 Health Care Stocks That May Collapse This Quarter ↗
 
Via Benzinga
News headline image
TERN Stock Earnings: Terns Pharma Meets EPS for Q4 2023 ↗
TERN stock results show that Terns Pharma met analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Terns Pharmaceuticals' Oral GLP-1 Reaches Phase 1 Finish Line With Encouraging Weight Loss Data After One Month ↗
Terns Pharmaceuticals announced promising Phase 1 trial results for TERN-601, showing significant weight loss in obese and overweight adults, with up to 4.9% placebo-adjusted mean weight loss at the... 
Via Benzinga
News headline image
The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race ↗
The race to develop the next big obesity treatment is on with leaders Lilly and Novo trying to keep their top slots. 
Via Investor's Business Daily
News headline image
TERN Stock Earnings: Terns Pharma Beats EPS for Q2 2024 ↗
TERN stock results show that Terns Pharma beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
3 Biotech Stocks That Could Have Investors Grinning Soon ↗
Biotech stocks are a high risk, high reward investment and these three biotechs offer significant upside potential. 
Via InvestorPlace
News headline image
Can These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs? ↗
At least one of the pair has a credible shot at finding a home in the market. 
Via The Motley Fool
News headline image
Recap: Terns Pharma Q3 Earnings ↗
 
Via Benzinga
News headline image
12 Analysts Have This to Say About Terns Pharma ↗
 
Via Benzinga
News headline image
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players' ↗
Eli Lilly and Novo Nordisk face selloff as new weight-loss drugs threaten dominance. Shares of both companies drop significantly, highlighting need for diversification in this industry. 
Via Benzinga
News headline image
Why ConAgra Brands Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Methode Electronics Posts Strong Sales, Joins QuantumScape, Ribbon Communications And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
TERN Stock Earnings: Terns Pharma Beats EPS for Q1 2024 ↗
TERN stock results show that Terns Pharma beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
Wall Street’s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich ↗
Some of the market’s favorite biotech stocks have created immense wealth, as evidenced with the recent weight-loss drug stock boom. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy? ↗
Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while. 
Via The Motley Fool
News headline image
Top 5 Health Care Stocks That Are Ticking Portfolio Bombs ↗
As of Dec. 5, 2023, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. 
Via Benzinga
News headline image
Why Take-Two Interactive Software Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Shares of Take-Two Interactive Software, Inc. (NASDAQ: TTWO) fell sharply during Friday’s session following third-quarter results. 
Via Benzinga
News headline image
SAIC Reports Q3 Results, Joins Uber, Wallbox And Other Big Stocks Moving Higher On Monday ↗
U.S. stocks traded lower, with the Dow Jones index falling more than 100 points on Monday. 
Via Benzinga
Topics Stocks
News headline image
Why U Power Shares Are Trading Lower By Around 54%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Shares of U Power Limited (NASDAQ: UCAR) shares moved lower during Monday’s session after the company announced pricing of registered follow-on offering of 10 million units at a purchase price of $1.20... 
Via Benzinga
News headline image
3 Biotechs Compete for the Same $108-Billion-Dollar Market. Are They a Buy? ↗
NASH treatments are projected to be one of the most sought-after indications in the coming years. 
Via The Motley Fool
News headline image
Looking for the Next Big Biopharma Stock? These 4 Letters Are 1 Big Clue Where to Find It ↗
NASH is a surprisingly common ailment, and the first treatments are on the way. 
Via The Motley Fool
News headline image
Global Payments To Rally Around 17%? Here Are 10 Other Analyst Forecasts For Thursday ↗
Keybanc cut the price target for i3 Verticals, Inc. (NASDAQ: IIIV) from $28 to $26. Keybanc analyst Josh Beck maintained an Overweight rating. i3 Verticals shares fell 2.9% to close at $22.76 on... 
Via Benzinga
News headline image
Terns Pharmaceuticals Is "Attractively Priced" Despite Pressure From Eli Lilly's Obesity Data, Analyst Says ↗
Tuesday, Terns Pharmaceuticals Inc (NASDAQ: TERN) shares lost more than 25% of their value due to investor pressure it faced after Eli Lilly And Co (NYSE: LLY) announced data from retatrutide that was... 
Via Benzinga
News headline image
Why Walgreens Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Tivic Health Systems, Inc. (NASDAQ: TIVC) shares jumped 105% to $0.2050 after the company signed a distribution agreement with Cardinal Health. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.